High expression level of T-box transcription factor 5 predicts unfavorable survival in stage I and II XXXX .

@entity1 @entity5 @entity1349 @entity356 @entity15775
UNASSIGNED: The expression of T-box transcription factor 5 ( @entity15775 ) has previously been observed in @entity1 @entity5 . The aim of the present study was to investigate @entity15775 expression and its potential clinical significance in @entity356 ( @entity356 ). Using reverse transcription-quantitative polymerase chain reaction, the @entity15775 mRNA expression levels in 30 pairs of surgically resected healthy gastric tissues and early stage (stages I and II) @entity356 tissues were evaluated. The @entity15775 mRNA expression levels were increased in @entity356 stage I and II @entity5 tissues (P=0.01, n=30) compared with the matched adjacent non- @entity5 tissue. However, no significant difference was observed in @entity15775 mRNA expression levels in matched adjacent non- @entity5 tissue compared with the @entity5 tissue from stage III and IV @entity356 samples (P=0.318, n=30). Immunohistochemical analysis for @entity15775 expression was performed on 161 paraffin-embedded stage I and II @entity356 tissue blocks. Statistical analysis was performed to evaluate the associations between @entity15775 expression, clinicopathological factors and prognosis. @entity1 with stage I and II @entity356 and @entity5 with high @entity15775 expression levels presented poor @entity1349 ( @entity1349 ) rate (P=0.024). The Cox proportional hazards model analysis demonstrated that @entity15775 expression was an independent risk factor (P=0.017). The present study indicates that high expression of @entity15775 is associated with unfavorable @entity1349 rates in @entity1 with stage I and II @entity356 . In conclusion, the expression of @entity15775 may be a valuable biomarker for the selection of cases of high-risk stage I and II @entity356 .
